Our Pricing

Mounjaro vs Wegovy Weight Loss Results: UK Clinical Evidence

Published on: June 03, 2026

When comparing mounjaro vs wegovy weight loss results uk, clinical trial data shows distinct differences in efficacy and mechanism. At Cured Pharmacy, our UK-registered clinical team helps patients understand these evidence-based outcomes to choose the most appropriate treatment, with transparent pricing from £135.00 and free online consultation under three minutes.

Clinical Trial Results: Mounjaro vs Wegovy Weight Loss Outcomes

The most rigorous head-to-head comparison comes from the SURPASS-2 trial, which directly compared tirzepatide (Mounjaro) against semaglutide 1mg in adults with type 2 diabetes. Participants receiving the highest tirzepatide dose (15mg) achieved an average body weight reduction of 11.2kg, compared to 5.7kg with semaglutide 1mg over 40 weeks [1]. This represents nearly double the weight loss with tirzepatide's dual-receptor mechanism.

In obesity-specific trials, the SURMOUNT-1 study demonstrated that Mounjaro produced average weight reductions of up to 22.5% of initial body weight over 72 weeks at the 15mg maintenance dose [2]. By comparison, the STEP-1 trial showed Wegovy (semaglutide 2.4mg) achieved average reductions of 14.9% over 68 weeks [3]. Both medications significantly outperformed placebo and lifestyle intervention alone, but tirzepatide consistently demonstrated superior efficacy across multiple endpoints.

It's important to note that individual responses vary considerably based on adherence, baseline metabolic health, and lifestyle factors. Your UK prescriber at Cured Pharmacy will assess your medical history, current medications, and weight loss goals to determine which treatment may be most appropriate for your circumstances.

How Mounjaro and Wegovy Work Differently

Mounjaro contains tirzepatide, the first dual GIP/GLP-1 receptor agonist licensed by the MHRA in the UK. It activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, creating a synergistic effect on appetite regulation, insulin secretion, and gastric emptying [1]. This dual mechanism appears to produce greater metabolic benefits than GLP-1 activation alone.

Wegovy contains semaglutide, a selective GLP-1 receptor agonist that has been extensively studied since its approval. Semaglutide works by mimicking the natural GLP-1 hormone, which reduces appetite through central nervous system pathways, slows gastric emptying, and improves glycaemic control [3]. While operating through a single pathway, semaglutide demonstrates robust efficacy and has the longest track record of real-world safety data among weekly injectable weight loss treatments.

Both medications require once-weekly subcutaneous injection and follow dose escalation schedules to minimise gastrointestinal side effects. The choice between them often depends on individual response, tolerability, cost considerations, and prescriber assessment of your clinical profile.

Mechanism of Action: Why Dual Receptors May Offer Advantages

The addition of GIP receptor activation in tirzepatide appears to enhance fat metabolism and may reduce the gastrointestinal side effects commonly associated with GLP-1 agonists alone [2]. Preclinical studies suggest GIP improves insulin sensitivity in adipose tissue and may influence energy expenditure, though the exact mechanisms in humans continue to be investigated.

Clinical observations show that patients on tirzepatide often report better tolerability at higher doses compared to maximum-dose semaglutide, though individual experiences vary significantly. This may relate to the modulatory effect of GIP on gastric motility, potentially offsetting some of the nausea and vomiting associated with strong GLP-1 activation.

Mounjaro vs Wegovy: Side Effect Profiles and Tolerability

Both Mounjaro and Wegovy share similar side effect profiles, with gastrointestinal symptoms being most common. In clinical trials, nausea occurred in approximately 20-30% of participants on both medications, typically during dose escalation phases [1][3]. Diarrhoea, constipation, vomiting, and abdominal discomfort were also frequently reported, though most symptoms were mild to moderate and diminished over time.

The SURPASS trials showed that discontinuation rates due to adverse events were comparable between tirzepatide and semaglutide, ranging from 4-7% depending on dose [1]. Importantly, serious adverse events were rare with both treatments. However, both medications carry warnings for potential thyroid C-cell tumours based on rodent studies, and are contraindicated in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

At Cured Pharmacy, our UK prescribers conduct thorough medical assessments to identify contraindications and ensure appropriate monitoring. All patients receive detailed guidance on managing side effects, recognising warning signs, and when to seek medical attention. Both treatments require gradual dose titration, which significantly reduces the severity of initial gastrointestinal symptoms.

Managing Common Side Effects

Most gastrointestinal side effects can be minimised by eating smaller, more frequent meals, avoiding high-fat foods, and staying well-hydrated. Taking the injection on the same day each week and following the prescribed dose escalation schedule without rushing helps your body adapt to the medication gradually.

If you experience persistent vomiting, severe abdominal pain, or signs of pancreatitis (severe upper abdominal pain radiating to the back), contact your prescriber immediately. Both medications have been associated with rare cases of acute pancreatitis, and any concerning symptoms require prompt medical evaluation.

Cost Comparison: Mounjaro vs Wegovy Pricing at Cured Pharmacy

Pricing transparency is essential when considering long-term weight management treatments. At Cured Pharmacy, Mounjaro is available from £124.99 per month, while Wegovy starts from £135.00, with final costs determined by your prescribed maintenance dose following clinical assessment. Unlike some providers, we display upfront pricing before you complete your consultation, ensuring no unexpected costs.

The price difference reflects several factors, including manufacturing costs, market positioning, and supply chain considerations. Mounjaro, as the newer dual-receptor agonist, typically commands higher pricing across UK pharmacies. However, when evaluating cost-effectiveness, patients should consider the potentially greater weight loss outcomes demonstrated in clinical trials, which may justify the additional investment for some individuals.

Both treatments represent significant ongoing expenses, as weight management typically requires continuous therapy to maintain results. Our clinical team can discuss your budget considerations alongside clinical factors to identify the most appropriate and sustainable treatment plan. All prescription medications at Cured Pharmacy require online clinical assessment by a UK-registered prescriber, completed in under three minutes.

Who Should Choose Mounjaro vs Wegovy?

Clinical guidelines in the UK recommend GLP-1 receptor agonists for adults with a BMI of 30 kg/m² or above, or 27 kg/m² with weight-related comorbidities such as type 2 diabetes, hypertension, or obstructive sleep apnoea [4]. Both Mounjaro and Wegovy meet NICE criteria for weight management when prescribed alongside reduced-calorie diet and increased physical activity.

Mounjaro may be particularly suitable for patients who have not achieved adequate weight loss with semaglutide-based treatments, those with concurrent type 2 diabetes requiring robust glycaemic control, or individuals seeking maximum weight reduction based on clinical trial evidence. The dual-receptor mechanism offers a distinct pharmacological approach that some patients respond to more favourably.

Wegovy remains an excellent first-line option for most patients, particularly those concerned about cost, seeking a treatment with extensive real-world safety data, or who have previously tolerated GLP-1 agonists well. Many patients achieve significant, sustained weight loss with semaglutide 2.4mg, and it represents the most studied weekly injectable weight loss medication available in the UK.

Your Cured Pharmacy prescriber will evaluate your complete medical history, previous weight loss attempts, concurrent medications, and individual goals to recommend the most appropriate treatment. Factors such as kidney function, history of pancreatitis, diabetic retinopathy status, and cardiovascular risk profile all influence treatment selection.

Switching Between Treatments

Some patients may transition from Wegovy to Mounjaro if weight loss plateaus or side effects become problematic. Conversely, others may step down from Mounjaro to Wegovy for cost reasons once initial weight loss goals are achieved. Any treatment switch should be supervised by your prescriber to ensure appropriate dosing transitions and continued safety monitoring.

There is no required washout period when switching between semaglutide and tirzepatide, as both have similar pharmacokinetic profiles. Your prescriber will determine the appropriate starting dose based on your current treatment and tolerance, typically beginning at a lower dose to reassess tolerability with the new medication.

Long-Term Weight Maintenance: What the Evidence Shows

Extension studies from both the STEP and SURMOUNT programmes demonstrate that weight loss is maintained as long as treatment continues, but significant weight regain occurs upon discontinuation [2][3]. In the STEP-4 trial, participants who stopped semaglutide after 20 weeks regained approximately two-thirds of their lost weight over the subsequent 48 weeks, highlighting the chronic nature of obesity and the need for ongoing pharmacological support.

This underscores an important clinical reality: both Mounjaro and Wegovy are long-term treatments rather than short-term interventions. The MHRA licensing and NICE guidance reflect this understanding, positioning these medications as chronic disease management tools similar to treatments for hypertension or diabetes. Patients should approach these treatments with realistic expectations about duration and commitment to lifestyle modifications.

At Cured Pharmacy, our superintendent pharmacist Tarun Kumar (GPhC 2233073) and clinical team provide ongoing support throughout your weight management journey. We offer regular medication reviews, dose adjustments as needed, and guidance on integrating behavioural changes that support long-term success. Combining pharmacotherapy with sustainable dietary patterns and regular physical activity produces the best outcomes for lasting weight management.

Building Sustainable Habits Alongside Medication

While GLP-1 medications significantly reduce appetite and facilitate calorie restriction, they work best when combined with structured lifestyle interventions. Evidence suggests that patients who engage with dietetic support, establish regular exercise routines, and address psychological factors related to eating behaviours achieve superior long-term outcomes compared to medication alone.

Your prescriber can recommend NHS-approved weight management programmes, registered dietitians, and behavioural support resources to complement your pharmacological treatment. This integrated approach addresses obesity as the complex, multifactorial condition it is, rather than relying solely on medication to achieve lasting results.

Scientific References

1. Frías, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/NEJMoa2107519 [accessed 13 August 2026]
2. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
3. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
4. National Institute for Health and Care Excellence. (2023). Semaglutide for managing overweight and obesity. Technology appraisal guidance [TA875]. https://www.nice.org.uk/guidance/ta875 [accessed 13 August 2026]
5. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
6. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
7. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Weight loss results vary between individuals and depend on adherence to treatment, lifestyle modifications, and individual metabolic factors. Clinical trial results represent average outcomes and do not guarantee specific results for any individual patient.